Horng-Chih Huang - Chesterfield MO Timothy S. Chamberlain - Des Plaines IL Steven Lynn Settle - Wildwood MO William Dean Joy - Creve Coeur MO Ned R. Siegel - Belleville IL Leslie D. Bell - Chesterfield MO
The present invention provides for compounds having the following Formulae I-III, ##STR1## and ##STR2## The compounds of the present invention are useful in the treatment of a variety of disease such as glaucoma, sexual dysfunction, asthma and cardiovascular disorders such as stable-, unstable- and variant-angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, and thrombosis.
Modified Tissue Plasminogen Activator Substituted At Cysteine-73 And Lysine-277
Leslie D. Bell - Chesterfield MO Ernest J. Mayer - King of Prussia PA Mark O. Palmier - Webster Groves MO H. Eser Tolunay - Creve Coeur MO Thomas G. Warren - Ballwin MO Tze-Chein Wun - St. Louis MO
Assignee:
Monsanto Company - St. Louis MO
International Classification:
C12N 948 C12N 1558 C12P 2102 A61K 32547
US Classification:
435226
Abstract:
A modified tissue plasminogen activator having an improved in vivo half-life characterized in that the normal protein moiety of 527 amino acids is mutated at the site Cys73. fwdarw. Arg and at the site Lys277. fwdarw. Asp.
Modified Tissue Plasminogen Activator With Modified Glycosylation Site
Leslie D. Bell - Chesterfield MO Ernest J. Mayer - St. Louis MO Mark O. Palmier - Webster Groves MO H. Eser Tolunay - Creve Coeur MO Thomas G. Warren - Ballwin MO Tze-Chein Wun - St. Louis MO
Assignee:
Monsanto Company - St. Louis MO
International Classification:
C12N 948 C12N 1558 C12P 2102 A61K 37547
US Classification:
424 9464
Abstract:
A modified t-PA having improved in vivo half-life is disclosed comprising in sequence a fibronectin finger-like domain F, a growth factor domain GF, a sequence of two K2 kringle regions and a serine protease region SP, wherein the first of said kringles is free of any glycosylation site and the second of said kringles has a single glycosylation site.
Tissue Plasminogen Activator Modified By The Substitution Of Arg For Cys At Position 73, Methods And Pharmaceutical Compositions Therefor
Leslie D. Bell - Chesterfield MO Ernest J. Mayer - St. Louis MO Mark O. Palmier - Webster Groves MO H. Eser Tolunay - Creve Coeur MO Thomas G. Warren - Ballwin MO Tze-Chein Wun - St. Louis MO
Assignee:
Monsanto Company - St. Louis MO
International Classification:
C12N 948 C12N 1558 C12N 2102 A61K 37547
US Classification:
424 9464
Abstract:
A modified tissue plasminogen activator having an improved in vivo half-life characterized in that the normal protein moiety of 527 amino acids is mutated at the site Cys73. fwdarw. Arg.
Leslie D. Bell - Chesterfield MO Ernest J. Mayer - St. Louis MO Mark O. Palmier - Webster Groves MO H. Eser Tolunay - Creve Coeur MO Thomas G. Warren - Ballwin MO Tze-Chein Wun - St. Louis MO
Assignee:
Monsanto Company - St. Louis MO
International Classification:
C12N 948 C12N 1558 C12P 2102 A61K 37547
US Classification:
424 9464
Abstract:
A modified t-PA having improved in vivo half-life is disclosed comprising in sequence a sequence of two K2 kringle regions and a serine protease region SP.